Indeed, but you mentioned prevention, and there are a lot of prevention activities that reside in pharma. I have contributed to the study of preventive measures in a whole range of settings, with a pharma perspective. The fact that you're looking at something from a pharma perspective doesn't stop you from looking at issues in a holistic way and extracting lessons that could benefit CIHR.
On November 30th, 2009. See this statement in context.